A pilot study of L-carnitine supplement for liver cirrhosis

A pilot study of L-carnitine supplement for liver cirrhosis - L-carnitine supplement for liver cirrhosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009188

Enrollment

Registered

2012-10-25

Start date

2012-10-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cirrhosis

Interventions

Oral administration of levocarnitine chloride

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Histologically proven or clinically diagnosed liver cirrhosis 2) Hyperammonemia 3) Adequate organ function 4) Life expectancy of at least 3 months 5) Written informed consent

Exclusion criteria

Exclusion criteria: 1) Severe hepatic encephalopathy 2) Refractory pleural effusion or ascites 3) Jaundice 4) Concurrent disease a) Severe renal disease b) Serious hypertension c) Severe heart disease d) Acute myocardial infarction within 6 months prior to inclusion e) Active cancer f) Severe mental disorder g) Severe drug allergy 5) Pregnant and lactating females; females of childbearing age unless using effective contraception 6) Patients who are concluded to be inappropriate to participate in this study by their physicians

Design outcomes

Primary

Measure	Time frame
Blood ammonia levels	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026